Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 13/20 | 0.74 |
| ▸ | JAK2 | O60674 | 9/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792963 | 0.85 | TYK2 (1.00) | TYK2JAK2MALT1ABL1NPC1 | |
| SCHEMBL11960387 | 0.84 | TYK2 (0.65) | TYK2JAK2ABL1NPC1RAB9A | |
| SCHEMBL793342 | 0.82 | TYK2 (0.81) | TYK2JAK2MALT1ABL1MEN1 | |
| SCHEMBL11900120 | 0.80 | TYK2 (0.47) | TYK2JAK2MALT1 | |
| SCHEMBL792091 | 0.79 | TYK2 (0.48) | TYK2JAK2 | |
| SCHEMBL792100 | 0.78 | TYK2 (0.67) | TYK2JAK2MALT1ABL1NPC1 | |
| SCHEMBL791839 | 0.77 | TYK2 (0.49) | TYK2 | |
| SCHEMBL11900124 | 0.77 | TYK2 (0.52) | TYK2RAB9AMEN1KMT2A | |
| SCHEMBL793928 | 0.76 | TYK2 (0.81) | TYK2JAK2 | |
| SCHEMBL792344 | 0.76 | TYK2 (0.65) | TYK2JAK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | TYK2 229/4885JAK2 544/4885MALT1 389/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | TYK2 229/4885JAK2 544/4885MALT1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.